Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Bone Marrow Transplant. 2016 May 23;51(10):1342–1349. doi: 10.1038/bmt.2016.142

Table 4. Aggregate analyses of all high-risk amino acid substitution position and type in the validation cohort.

Hazard Ratio 95% Confidence Interval p-value
Overall Survival1 No AAS (n=390) vs. 8/8 1.41 1.21-1.64 <0.0001
At least 1 AAS (n=354) vs. 8/8 1.43 1.23-1.66 <0.0001
At least 1 AAS vs. no AAS 1.01 0.83-1.23 0.91
Disease-Free Survival2 No AAS vs. 8/8 1.33 1.15-1.54 <0.0001
At least 1 AAS vs. 8/8 1.37 1.18-1.59 <0.0001
At least 1 AAS vs. no AAS 1.03 0.85-1.24 0.76
Treatment-Related Mortality3 No AAS vs. 8/8 1.65 1.37-1.99 <0.0001
At least 1 AAS vs. 8/8 1.66 1.36-2.01 <0.0001
At least 1 AAS vs. no AAS 1.00 0.79-1.28 0.97
Grades III-IV Acute GvHD4 No AAS vs. 8/8 1.75 1.34-2.30 <0.0001
At least 1 AAS vs. 8/8 1.58 1.18-2.10 <0.002
At least 1 AAS vs. no AAS 0.90 0.63-1.28 0.55
1

Adjusted for patient age, CMV match, conditioning, donor age, disease status, KPS; stratified by graft type.

2

Adjusted for patient age, CMV match, donor age, disease status, KPS, year of transplantation; stratified by graft type and disease type.

3

Adjusted for patient age, donor age, disease, disease status, KPS; stratified by graft type.

4

Adjusted for patient sex; stratified by graft type.

Abbreviations: AAS, high-risk AASPT defined by the training dataset; GvHD, graft-versus-host disease; CMV, cytomegalovirus